Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies

Bruton tyrosine kinase (BTK), a clinically validated target for various B-cell malignancies, plays a critical role in regulating cell growth, adhesion and homing to key lymphoid tissues that provide a microenvironment favorable to cancer cells. Despite the success of approved covalent BTK inhibitors...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.1887-1887
Hauptverfasser:	Pan, Chin, Gururaja, Tarikere L, Li, Haiyan, Nguyen, Henry, Zhai, Yongjiao, Xie, Xiaoping, Ding, Rong-Xian, Mathew, Rebecca, Hoh, Hana Y, Jia, Zhaozhong J, Liu, Bo, Shu, Cassandra, Assaily, Wissam, Lam, Lloyd T, Riehm, Jacob J, Stevenson, Claudina, Will, Christine, Innocenti, Federico, Rivkin, Alexey
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!